Lipocine Inc. Announces Milestone Payment from Abbott Laboratories
SALT LAKE CITY--(BUSINESS WIRE)--Lipocine Inc. (www.lipocine.com) announced today the receipt of a $2 million development milestone payment from Abbott under the terms of its Licensing Agreement to develop and commercialize an oral testosterone product for hypogonadism, also known as low testosterone (low T).